Second transplantation using allogeneic peripheral blood stem cells in a β-thalassaemia major patient featuring stable mixed chimaerism

R. Or*, J. Kapelushnik, E. Naparstek, A. Nagler, D. Filon, A. Oppenheim, A. Amar, M. Aker, S. Samuel, S. Slavin

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Allogeneic bone marrow transplantation (BMT) for β-thalassaemia major carries the risks of disease recurrence due to residual thalassaemic stem cells or true immune-mediated rejection. We report a thalassaemic patient who displayed stable mixed chimaerism with only 5% donor-derived cells for about 5 years after BMT. Displacement of host cells was accomplished by ambulatory non-myeloablative conditioning and allogeneic G-CSF mobilized peripheral blood stem cell transplantation from the same donor, resulting in full reconstitution. Patients featuring stable mixed chimaerism after BMT may benefit from allogeneic cell therapy with immunocompetent lymphocytes and stem cells, whilst avoiding supralethal conditioning.

Original languageEnglish
Pages (from-to)285-287
Number of pages3
JournalBritish Journal of Haematology
Volume94
Issue number2
DOIs
StatePublished - 1996
Externally publishedYes

Keywords

  • bone marrow transplantation
  • peripheral blood stem cell transplantation
  • stable mixed chimaerism
  • β-globin gene
  • β-thalassaemia major

Fingerprint

Dive into the research topics of 'Second transplantation using allogeneic peripheral blood stem cells in a β-thalassaemia major patient featuring stable mixed chimaerism'. Together they form a unique fingerprint.

Cite this